Economy, business, innovation

Markets

Sezzle Inc. (SEZL) Jumps 6.4% to $65.25

SEZL Price $65.25 Change +6.4% Volume 162,024 Sezzle Inc. surged 6.4% to $65.25 on Tuesday as the buy-now-pay-later provider announced the launch of its virtual card in Canada with Marqeta, expanding its payment network to both in-store and online transactions across major retailers. The catalyst driving today’s rally is a significant product expansion. According to […]

Sezzle Inc. (SEZL) Jumps 6.4% to $65.25 Read More »

WisdomTree, Inc. Jumps 8.3%

WT Price $17.75 Change +8.3% Volume 1.1M WisdomTree shares jumped 8.3% on Tuesday as a broad rally lifted asset managers across the board. The exchange-traded fund provider closed at $17.75 on volume of 1.1M shares, riding a wave of momentum that pushed multiple sector peers sharply higher during the session. The move wasn’t company-specific. WisdomTree’s

WisdomTree, Inc. Jumps 8.3% Read More »

Ichor Holdings, Ltd. Shares Jumps 8%

ICHR Price $65.57 Change +8% Volume 421,526 Ichor Holdings jumped 8% on Tuesday to close at $65.57 after B. Riley Securities lifted its price target by 44.2%, signaling renewed confidence in the semiconductor equipment supplier’s growth trajectory. The catalyst came from a major analyst endorsement. B. Riley Securities maintained its Buy rating while raising its price

Ichor Holdings, Ltd. Shares Jumps 8% Read More »

Ligand Pharmaceuticals Incorporated Shares Jumping 9.2%

LGND Price $233.16 Change +9.2% Volume 181,442 Ligand Pharmaceuticals Incorporated surged 9.2% on Tuesday, April 14, 2026, climbing to $233.16 after HC Wainwright & Co. raised its price target on the biotechnology company. The stock traded 181,442 shares as the firm maintained its Buy rating while lifting its target to $243 from $239, representing a

Ligand Pharmaceuticals Incorporated Shares Jumping 9.2% Read More »

Prothena FY25 Earnings Review: Partnered Programs Advance Toward Milestones as Wholly-Owned Assets Pivot

Business Overview Prothena Corporation plc operates as a late-stage clinical biotechnology company focusing predominantly on the science of protein dysregulation. The firm aims to alter the clinical course of devastating neurodegenerative and rare peripheral amyloid diseases. Prothena’s scientific foundation is built on decades of research regarding misfolded proteins and neurological dysfunction. The company’s pipeline consists

Prothena FY25 Earnings Review: Partnered Programs Advance Toward Milestones as Wholly-Owned Assets Pivot Read More »

FB Financial Corporation Posts 32% Revenue Jump in Q1

FBK|EPS $1.12 vs $1.13 est (-0.9%)|Rev $172.3M|Net Income $57.5M Stock $54.65  Narrow Miss. FB Financial Corporation (NYSE:FBK) reported Q1 2026 adjusted diluted earnings of $1.12 per share, falling just short of the $1.13 consensus estimate by 0.9%. Despite the modest earnings shortfall, the Nashville-based regional bank delivered a strong revenue performance, generating $172.3M for the

FB Financial Corporation Posts 32% Revenue Jump in Q1 Read More »

Scroll to Top